drugset
drugset / Trial / NCT04983940

Patient Satisfaction After Switching to Oral Testosterone Undecanoate

NCT04983940 ↗

Phase 4 Completed 41 enrolled University of Miami Clarus Therapeutics, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to evaluate patient satisfaction with an oral testosterone agent, Jatenzo, compared to other forms of testosterone therapy.

Timeline

Start
2021-06-18
Primary completion
2023-04-06
Completion
2023-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Undecanoate Small molecule 237 mg Oral

Indications

hypogonadism, male